Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-04T18:40:46.715Z Has data issue: false hasContentIssue false
  • English
  • Français

Estudio meta-analítico de los beneficios y riesgos de tratar la esquizofrenia crónica con risperidona o neurolépticos convencionales

Published online by Cambridge University Press:  12 May 2020

P. Bech ,
J. C. J. R. Peuskens ,
S. R. Marder ,
G. Chouinard ,
O. J. Høyberg ,
M. O. Huttunen ,
O. Blin  and
A. Claus
P. Bech
Affiliation:
Unidad de Psiquiatría, Hospital General Frederiksborg, Hillerøo Sygehus, DK-3400, Hillerød, Dinamarca
J. C. J. R. Peuskens
Affiliation:
Centro Universitario St. Jozef, Kortenberg, Bélgica
S. R. Marder
Affiliation:
Centro Médico West Los Angeles VA, Los Angeles, CA, EE.UU.
G. Chouinard
Affiliation:
Hospital Louis-H. Lufontaine, Montreal, Quebec, Canadá
O. J. Høyberg
Affiliation:
Departamento de Psiquiatría, Hospital Molde, Molde, Noruega
M. O. Huttunen
Affiliation:
Departamento de Psiquiatría, Universidad de Helsinki, Finlandia
O. Blin
Affiliation:
Hospital de la Timone, Marseille, Francia
A. Claus
Affiliation:
Hospital Universitario Psiquiátrico St. Camillus, Birbeek, Bélgica
Get access

Resumen

Se analizaron los datos de seis estudios comparativos controlados distribuidos al azar de risperidona y neuroleptics convencionales (haloperidol, zuclopentixol y perfenazina) en el tratamiento de 911 pacientes con esquizofrenia crónica para estimar los beneficios y riesgos del tratamiento. Se evaluó la eficacia y el riesgo del tratamiento por medio de la Escala del Síndrome Positivo y Negativo (PANSS) y la Escala de Evaluación de Síntomas Extrapiramidales (ESRS). A partir de las puntuaciones de la PANSS y la ESRS, se calculó la eficacia del efecto (la diferencia entre los tratamientos). La eficacia del efecto antipsicótica fue favorable a la risperidona (iba de 0,22 a 0,37 en las subescalas de la PANSS), y el nivel de la seguridad también (iba de 0,18 a 0,36 en la ESRS). Un análisis de la proporción de pacientes que precisaron medicación antiparkinsoniana produjo un nivel del efecto de 0,37 (precisaron medicación anti-Jarkinsoniana el 20% de los pacientes con risperidona y el 38% de los pacientes que recibían un neuroléptico convencional). Estos datos indican que la risperidona es un antipsicótico más efectivo que los agentes convencionales y causa síntomas extrapiramidales menos graves.

Keywords

meta-análisis de la esquizofreniarisperidonaeficaciatolerabilidad
Type
Artículo original
Information
European Psychiatry (Ed. Española) , Volume 6 , Issue 2 , March 1999 , pp. 100 - 105
Copyright
Copyright © European Psychiatric Association 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bibliografía

American Psychiatric Association. Diagnostic and statistical Manual of Mental Disorders 3rd ed rev (DSM-III-R). Washington: American Psychiatric Association; 1987.Google Scholar
Andreasen, NCOlsen, SA.Negative versus positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39: 789–94.CrossRefGoogle Scholar
Bech, PCialdella, P.Citalopram in depression: metaanalysis of intented and unintended effects. Int Clin Psychopharmacol 1992; 6 suppl 5: 45–54.CrossRefGoogle Scholar
Blin, OAzorin, JMBouhours, P.Antipsychotic and anxiolytic properties of risperidone, haloperidol, and levomepromazine in schizophrenic patients. J Clin Psychopharmacol 1996; 16: 38–44.CrossRefGoogle ScholarPubMed
Borison, RLPathiraja, APDiamond, BIMeibach, RC.Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213–8.Google Scholar
Carman, JPeuskens, JVangeneugden, A.Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 207–13.CrossRefGoogle ScholarPubMed
Chouinard, GRoss-Chouinard, AAnnable, LJones, BD.Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7; 233.Google Scholar
Chouinard, GJones, BRemington, GBloom, DAddington, DMacEwan, GW, et al.A Canadian mul-ticenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25–40.CrossRefGoogle ScholarPubMed
Claus, ABollen, JDe Cuyper, HEneman, MMalfroid, MPeuskens, JHeylen, S.Risperidone versus haloperidol in the treatment of chronic schizophrenic in patients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295–305.CrossRefGoogle ScholarPubMed
Cohen, J.Statistical Power Analysis for the Behavioral Sciences. Orlando: Academic Press; 1977.Google Scholar
Davis, JMJanicak, PG.Risperidone: a new, novel (and better)? antipsychotic. Psychiatr Ann 1996; 26: 78–87.CrossRefGoogle Scholar
Glass, GV.Integrating findings: the meta-analysis of research. Rev Educ Res 1977; 5: 351–79.Google Scholar
Greenberg, RPBornstein, RFZborowski, MJFisher, SGreenberg, MD.A meta-analysis of fluoxetine out-come in the treatment of depression. J Nerv Ment Dis 1994; 192: 547–51.CrossRefGoogle Scholar
Guy, W.Early Clinical Drug Evaluation (ECDEU) Assessment Manual. Rockville: National Institute of Mental Health; 1976.Google Scholar
Høyyberg, OJFensbo, C.Remvig, JLingjaerde, OSloth-Nielsen, MSalvesen, I.Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 1993; 88: 395–402.CrossRefGoogle Scholar
Huttunen, MOPieponnen, TRantanen, HLarmo, INyholm, RRaitasuo, V.Risperidone versus zuclo-penthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial. Acta Psychiatr Scand 1995; 91: 271–7.CrossRefGoogle ScholarPubMed
Kane, JM.Risperidone. Am J Psychiatry 1994; 151: 802–3.Google ScholarPubMed
Kane, JHonigfeld, GSinger, JMeltzer, H.Clozaril Collaborative Study Group. Clozapine for the treat-ment-resistant schizophrenic: a double-blind comparison with haloperidol. Arch Gen Psychiatry 1988;, 45:789–96.CrossRefGoogle Scholar
Kay, SRFiszbein, AOpler, LA.The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76.CrossRefGoogle Scholar
Leysen, JEGommeren, WEens, A.De Chaffoy de Courcelles, DStoof, JCJanssen, PAJ.The biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247: 61–70.Google ScholarPubMed
Lieberman, JAJohns, CAKane, JMRai, K.Clozapine-induced agranulocytosis: on non-cross reactivity with other psychotropic drugs. J Clin Psychiatry 1988; 49:271–7.Google ScholarPubMed
Marder, SRMeibach, RC.Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825–35.Google ScholarPubMed
Meltzer, HYMatsubara, SLee, JC.Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-l, D-2, and serotonin 2 pKi values. J Pharmacol Exp Ther 1989; 251: 238–49.Google Scholar
Moller, HJMuller, HBorison, RLSchooler, NRChourard, G.A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995; 245: 45–9.CrossRefGoogle ScholarPubMed
Overall, JEGorham, DR.The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10: 799–812.CrossRefGoogle Scholar
Peuskens, J, the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712–26.CrossRefGoogle Scholar